Across TCGA pan-cancer cohorts, ZBTB40 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZBTB40 data layer compared with 25 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZBTB40 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZBTB40 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.
PDAC, LUAD, and LSCC are the cancer types where ZBTB40 mass-spec protein most reproducibly stratifies survival.